Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12747761 | 0.99 | KCNH2 (0.38) | KCNH2CYP4F2CYP4A11NPSR1LTB4R | |
| SCHEMBL12747700 | 0.85 | KCNH2 (0.38) | KCNH2CYP4F2CYP4A11 | |
| SCHEMBL12747691 | 0.85 | KCNH2 (0.38) | KCNH2CYP4F2CYP4A11 | |
| SCHEMBL12747803 | 0.84 | CYP1A2 (0.34) | SIRT2CYP1A2IRAK4 | |
| SCHEMBL12747751 | 0.84 | LTB4R (0.41) | KCNH2CYP4F2CYP4A11LTB4RCYP1A2 | |
| SCHEMBL12747760 | 0.83 | LTB4R (0.43) | KCNH2CYP4F2CYP4A11LTB4RCYP1A2 | |
| SCHEMBL12747714 | 0.81 | HTR7 (0.47) | LTB4R | |
| SCHEMBL12747735 | 0.80 | HTR7 (0.46) | CYP4F2CYP4A11LTB4R | |
| SCHEMBL12747773 | 0.78 | IRAK4 (0.39) | CYP4F2CYP4A11IRAK4 | |
| SCHEMBL15418113 | 0.76 | MTNR1A (0.39) | NPSR1FAAHSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAK2, JAK1, JAK3 | KCNH2 2447/4885CYP4F2 1777/4885CYP4A11 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.